boehringer ingelheim respiratory products reglan

Today is #WorldCancerDay! © 2010-2020 Boehringer Ingelheim. ... (464.8 KB) Cancer Immunology @ Boehringer Ingelheim. "The hardest thing is not being able to do the things I used to do" say 1 in 4 of our #IPF ... Boehringer Ingelheim RCV GmbH & Co KG exports biopharmaceutical drugs developed and manufactured - to treat cancer and certain forms of immunodeficiency, for example - to countries throughout the world. We want to be part of this transformation. All rights reserved. The information on this page is only intended for residents of Australia. Our pharmaceutical products encompass a broad spectrum of therapeutic areas. Since scarring of the lung that has already occurred cannot be Accessibility Statement; Terms of Use; Data Privacy; Imprint; © 2010-2020 Boehringer Ingelheim. Our focus is on improving the quality of life of patients suffering from debilitating respiratory diseases and enabling them to maintain a more independent life.IPF affects as many as 14-43 people per 100,000 worldwide.Individuals with IPF may experience symptoms such as breathlessness during activity, a dry and persistent cough, chest discomfort and finger clubbing.Diagnosing IPF can be difficult because it requires specific diagnostic testing, such as lung imaging using a high-resolution CT scan.Over 80% of patients with IPF have a distinctive, VelcroEarly and accurate diagnosis of IPF is important, as management options such as pharmacological treatment, supplemental oxygen treatment, cough management and pulmonary rehabilitation (which can include special exercises or breathing techniques) may help patients manage their condition and maintain their quality of life.The prognosis for those diagnosed with IPF varies, but approximately half of the patients die within 2–3 years after diagnosis.Until recently, treatment options for IPF have been limited.

on We've gone blue to raise awareness of colorectalcancer this Colorectal Cancer Awareness Month ...the video on When it comes to outsmarting cancer we are brighter togetherthe video on Personalising cancer care and the future of cancer treatmentsthe video on Head and Neck Cancer incidence and prognosison Today is #WorldCancerDay! Since 1921 we have emerged as a leader in this disease area, having launched several treatments in a range of respiratory conditions including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and lung cancer. Two treatments have now been approved in the United States, European Union, Japan and other territories for the treatment of IPF and several other compounds are currently being studied in clinical trials. You can view a copy of the Consumer Medicine Information (CMI) for each product by clicking the product name. All rights reserved. Select your area of interest / professional background. Search . Respiratory. View PDF of Cancer Immunology @ Boehringer Ingelheim. We've gone blue to raise awareness of colorectalcancer this Colorectal Cancer Awareness Month ... ✋✋ ... Boehringer Ingelheim (Philippines), Inc. 23rd Floor Citibank Tower 8741 Paseo de Roxas Salcedo Village, Makati City 1227, Philippines Phone: +632 8867-0800 In the words of Ronald Reagan is there someone you could #help? These products are listed below by brand name in alphabetical order. Boehringer Ingelheim has over 90 years of heritage in managing respiratory disease. It also offers the range of innovative drugs from Boehringer Ingelheim … IPF; Animal Health. About ... Poultry; Livestock; Equine; Products; Careers; Search form. There is a high unmet need for safe and effective treatments that can alter the course of IPF by slowing disease progression. In the words of Ronald Reagan is there someone you could #help? Prescription Medicine - information about our products for Australian consumers. Boehringer Ingelheim has over 90 years of heritage in respiratory disease. on "The hardest thing is not being able to do the things I used to do" say 1 in 4 of our #IPF ...the video on Patient with IPF explains how the disease affects his everyday lifeWe recognize that the Internet serves a global community. Respiratory.

Results from a global survey on treatment considerations and selection in EGFR M+ NSCLCImproving the use of EGFR mutation testing in advanced non-small cell lung cancer – Insights from around the worldInnovative research to improve lives for patients with cancerFor more than 20 years, we are taking cancer on by developing novel therapies with attention to two indication areas: lung cancer and gastrointestinal tumors.At Boehringer Ingelheim, we believe this can be the generation that redefines many cancers as curable diseases. Since 1921 we have emerged as a leader in this disease area, having launched several treatments in a range of respiratory conditions including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and lung cancer. Since 1921 we have developed into the leading company in this sector, among other things through the launch of treatments for pulmonary and respiratory diseases like asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), and lung cancer. Boehringer Ingelheim has over 90 years of heritage in respiratory disease. Boehringer Ingelheim has over ninety years’ experience in treating respiratory and pulmonary diseases. Media backgrounder on idiopathic pulmonary fibrosis Since 1921 we have emerged as a leader in this disease area, having launched several treatments in a range of respiratory conditions including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and lung cancer. In addition the registration status of pharmaceutical products may not be the same in different regions of the world and the approved product labels may also differ according to country specific requirements. All rights reserved. The pharmaceutical industry, however, is subject to country specific regulatory considerations, which affect the information we can provide on our products. Boehringer Ingelheim is a leader in respiratory disease, having launched several treatments in a range of respiratory conditions including asthma, COPD and IPF.